Clinical Trial Update: CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating CAE Plus long-acting injectable in individuals with bipolar disorder at risk for treatment non-adherence; results posted after completi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• CAE Plus LAI (not specified)

Snippet

Sponsor: Martha Sajatovic | Conditions: Bipolar Disorder, Medication Adherence | Phase 4 | Status: COMPLETED | Results posted: 2022-02-17